MaxCyte, Inc.

NASDAQ:MXCT

Medical - Devices

Healthcare
$1.25 +3.98%

+$0.05 today

Market cap
$129.06M
Beta
1.67
P/E (TTM)
-3.2
EPS (TTM)
-$0.37
52W Low $0.64High $2.37

Volume 0.97M

Average 0.95M

MXCT Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

MaxCyte, Inc.NASDAQ: MXCT

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue declines year over year

Q1 FY2026 revenue of $9.65M fell 7.1% year over year, ahead of the -14.3% change in trailing-twelve-month revenue. Sequentially, it rose 32.2% from the prior quarter. Over 3 fiscal years it compounded at -9.3% a year.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 3 analysts of $34.08M (+3.2%) for the fiscal year ending Dec 2026, a step up from the -14.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.65M+32.2% QoQ
Last fiscal yearDec 2025
$33.03M-14.5% YoY
LTMMar 2026
$32.29M-14.3% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.1%-23.5%-16.4 pp
1 year-14.5%+3.2%+17.7 pp
3-year CAGR-9.3%+20.3%+29.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
33.03M USD
Year-over-year change
-14.5%
4-year CAGR
-0.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How MXCT compares with its peers on the latest reported figures

  • MXCT's LTM Mar 2026 revenue of $32.29M is the 6th highest of the 11 companies compared; the peer median is $26.71M.
  • Its year-over-year change of -14.3% is the 7th highest of 11, against a peer median of +8.3%.
  • Over three fiscal years its annual growth of -9.3% compares with a peer median of +15.0%.
MXCT Competitors Peer median
Revenue for MXCT and competitors
Company Period LTM YoY 3-year CAGR
PREPrenetics Global LimitedLTM Mar 2026$113.75M +174.0%+91.5%
OWLTOwlet, Inc.LTM Mar 2026$107.06M +26.8%+15.2%
LNSRLENSAR, Inc.LTM Mar 2026$57.7M +1.1%+18.2%
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$44.88M +39.6%+53.9%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$34.56M -45.8%-29.2%
MXCTMaxCyte, Inc.LTM Mar 2026$32.29M -14.3%-9.3%
PROFProfound Medical Corp.LTM Mar 2026$18.87M +34.8%+34.8%
NNOXNano-X Imaging Ltd.LTM Dec 2025$13.02M +15.4%+14.9%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$2.96M -37.1%-3.8%
AVRAnteris Technologies Global Corp.LTM Mar 2026$1.85M -25.7%-15.8%
CATXPerspective Therapeutics, Inc.LTM Mar 2026$618K -58.0%-50.1%
Peer median (excluding MXCT) $26.71M+8.3%+15.0%

Competitors are the stored peer set for MXCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.89M44.26M41.29M38.63M33.03M
Cost of Revenue3.65M5.1M4.74M7.1M6.22M
Gross Profit30.25M39.16M36.55M31.53M26.8M
Gross Margin89.2%88.5%88.5%81.6%81.2%
Research & Development15.41M19.51M23.82M22.23M20.82M
Selling, General & Admin31.68M44.48M57.04M56.35M47.04M
Operating Expenses48.44M66.52M84.85M82.72M72.09M
Depreciation & Amortization1.42M2.7M4.17M4.79M5.14M
EBITDA(16.61M)(20.75M)(33.75M)(36.27M)(39.49M)
EBITDA Margin-49.0%-46.9%-81.7%-93.9%-119.6%
Operating Income(18.19M)(27.36M)(48.3M)(51.2M)(45.29M)
Operating Margin-53.7%-61.8%-117.0%-132.5%-137.1%
Interest Income150.8K3.92M10.38M10.14M7.27M
Interest Expense1.04M126.9K000
Other Income / Expenses(893.6K)3.79M10.38M10.14M655K
Income Before Tax(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Pre-Tax Margin-56.3%-53.3%-91.8%-106.3%-135.1%
Income Tax Expense00000
Net Income(19.08M)(23.57M)(37.92M)(41.06M)(44.63M)
Net Margin-56.3%-53.3%-91.8%-106.3%-135.1%
EPS (Basic)(0.22)(0.19)(0.37)(0.39)(0.42)
EPS (Diluted)(0.22)(0.19)(0.37)(0.39)(0.42)
Weighted Avg Shares90.62M101.7M103.27M104.85M106.43M
Weighted Avg Shares (Diluted)90.62M101.7M103.27M104.85M106.43M

MaxCyte, Inc.

NASDAQ:MXCT

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.